A139 Agreement of Ibdoc® and Quanton Cal® Rapid Lateral Flow-Based Fecal Calprotectin Tests With Accepted Lab-Based Assays for Monitoring Inflammatory Bowel Disease

Sutton, Reed T.; Prosser, Connie; Dhami, Neil; Sadowski, Daniel C.; Zanten, Sander van; Kroeker, Karen I.; Wong, Kenneth; Halloran, Brendan P.; Fedorak, R; Huang, Vivian

doi:10.1093/jcag/gwy009.139

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We assume that no bias has been introduced due to the used (different) tests, since a good correlation between the QoC and other ELISA laboratory tests (Bühlmann Turbo) has been reported in the literature, as well as a similar accuracy for mucosal inflammation. 38 – 40 Thirdly, the sample size of our study is relatively small, and therefore subgroup analyses, including the separate analysis in UC and CD, might have been underpowered to detect differences. It is unlikely that the combined analysis of CD and UC has significantly influenced our results, since all patients with FC <250 µg/g at week 8 had endoscopic response at week 16; this value may serve as a cut-off to identify responders both in UC and in CD.…”

Section: Discussionmentioning

confidence: 96%

Fecal calprotectin is an early predictor of endoscopic response and histologic remission after the start of vedolizumab in inflammatory bowel disease

Pauwels

Woude

Erler

et al. 2020

Therap Adv Gastroenterol

View full text Add to dashboard Cite

Background and aims: Early prediction of the effect of vedolizumab (VDZ) in inflammatory bowel disease (IBD) is of paramount importance to guide clinical decisions. This study assessed whether early fecal calprotectin (FC) can predict endoscopic response and histologic remission after VDZ initiation. Methods: This was a prospective study. Inclusion criteria were endoscopic inflammation and FC >100 µg/g. FC was determined at baseline and weeks 2, 4, 8 and 16. At week 16, endoscopies with ileal and colonic biopsies were performed. FC changes were assessed with Wilcoxon Rank Sum tests. ROC statistics were used to assess the diagnostic accuracy of FC. Results: In total, 45 patients [27 Crohn’s disease (CD), 16/2 ulcerative colitis (UC)/IBD-unclassified] [40% males, median age 39 (28–51) years] were included. Week 16 endoscopic response and histologic remission rates were 58% and 33%. A median 37% decline in FC at week 2 was observed only in endoscopic responders, p = 0.025. FC <250 µg/g at week 8 predicted endoscopic response in both UC and CD (positive predictive value 100%), whereas absence of FC decline at week 8 corresponded with absence of endoscopic response in CD [negative predictive value (NPV) 82%] and absence of histologic remission in both UC and CD (NPV 90%). Conclusion: The onset of a decline in FC as early as week 2 is associated with endoscopic response to VDZ induction. FC <250 µg/g at week 8 is associated with endoscopic response, whereas absence of FC decline at week 8 is associated with absence of both endoscopic response and histologic remission. FC levels 8 weeks after the start of VDZ could be used to guide clinical decisions and might substitute for endoscopic response evaluation.

show abstract

Section: Discussionmentioning

confidence: 96%